Elacytarabine | CP-4055 | Anticancer Agent | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / 核苷抗代谢物 / Elacytarabine

Elacytarabine {[allProObj[0].p_purity_real_show]}

货号：A316040 同义名： CP-4055; CP 4055

CP 4055 (Elacytarabine) is a lipid-conjugated derivative of the nucleoside analog cytarabine. CP 4055 is an antineoplastic drug with cytotoxicity in solid tumors.

Elacytarabine 化学结构
CAS号：188181-42-2

Elacytarabine 3D分子结构
CAS号：188181-42-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Elacytarabine 纯度/质量文件产品仅供科研

货号：A316040 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: 更多 >

Elacytarabine 生物活性

描述

The clinical activity of cytarabine (ara-C) can be impaired by a deficient cellular drug uptake due to a reduced expression of nucleoside transporters in cancer cells. CP-4055, the 5’-elaidic acid esters of ara-C, has been synthesized to overcome the resistance caused by limited cellular uptake. Parental CEM cells presented a sensitivity to CP-4055 with a mean drug concentration resulting in 50% growth inhibition (GI50) of approximately 0.01 µM relative to untreated cells after 72 h treatment. CP-4055 induced high levels of annexin-V positive cells, while no apoptosis induction was observed after treatment of CEM/araC/8C cells with ara-C. Thus, the increase in cytotoxic activity observed after treatment of CEM/araC/8C cells with CP-4055 was principally because of an increase in apoptosis induction compared to the parental drug ara-C. Treatment of CEM cells with CP-4055 showed a classical arrest of cell cycle in the S-phase^[1]. In preclinical and clinical studies, CP-4055 has demonstrated both safety and efficacy in acute myeloid leukemia (AML), with noteworthy activity among the cytarabine-refractory AML population^[2].

Elacytarabine 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00232726	Malignant Melanoma ... 展开 >> Neoplasm Metastasis 收起 <<	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213-2584 Norway The Norwegian Radium Hospital Oslo, Norway, NO-0310 Sweden University Hospital Lund, Sweden, SE-221 85 收起 <<
NCT01147939	Acute Myeloid Leukemia (AML)	Phase 3	Completed	-	-
NCT00498836	Malignant Melanoma	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Texas Cancer Therapy and Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 Norway The Norwegian Radium Hospital Oslo, Norway, NO-0310 Sweden Lund University Hospital Lund, Sweden, SE-221 85 Umeå University Hospital Umeå, Sweden Uppsala University Hospital Uppsala, Sweden, SE-751 85 收起 <<

Elacytarabine 参考文献

[1]Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol. 2009;144(2):273‐275

[2]DiNardo CD, O'Brien S, Gandhi VV, Ravandi F. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia [published correction appears in Future Oncol. 2015;11(10):1584]. Future Oncol. 2013;9(8):1073‐1082

Elacytarabine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.85mL

1.97mL

0.98mL

19.70mL

3.94mL

1.97mL

Elacytarabine 技术信息

CAS号	188181-42-2
分子式	C₂₇H₄₅N₃O₆
分子量	507.66
SMILES Code	O=C(CCCCCCC/C=C\CCCCCCCC)OC[C@H]([C@@H](O)[C@@H]1O)O[C@H]1N2C=CC(N)=NC2=O
MDL No.	MFCD19443751

别名	CP-4055; CP 4055
运输	蓝冰
InChI Key	FLFGNMFWNBOBGE-FNNZEKJRSA-N
Pubchem ID	6438895

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C

溶解方案

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00232726	Malignant Melanoma ... 展开 >> Neoplasm Metastasis 收起 <<	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213-2584 Norway The Norwegian Radium Hospital Oslo, Norway, NO-0310 Sweden University Hospital Lund, Sweden, SE-221 85 收起 <<
NCT01147939	Acute Myeloid Leukemia (AML)	Phase 3	Completed	-	-
NCT00498836	Malignant Melanoma	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Texas Cancer Therapy and Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 Norway The Norwegian Radium Hospital Oslo, Norway, NO-0310 Sweden Lund University Hospital Lund, Sweden, SE-221 85 Umeå University Hospital Umeå, Sweden Uppsala University Hospital Uppsala, Sweden, SE-751 85 收起 <<
NCT01035502	Acute Myeloid Leukemia	Phase 2	Completed	-	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 France CHU Lyon, Hospital Edouard Herriot Lyon, France, 69437 Institut Paoli-Calmettes Marseille, France, 13273 CHU Toulouse, Hospital Purpan Toulouse, France, 31059 Germany Charite University Hospital Benjamin Franklin Berlin, Germany, 12200 Universitätsklinikum Münster Münster, Germany Universitätsklinikum Ulm Ulm, Germany, D-89081 Norway Haukeland University Hospital Bergen, Norway 收起 <<
NCT01783964	Not Applicable as This is a Ma... 展开 >>ss Balance/Pharmacokinetic Study Performed in Healthy Subjects 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Quotient Clinical Ruddington, Nottngham, United Kingdom, NG11 6JS 收起 <<
NCT00498407	Advanced Colorectal Cancer ... 展开 >> Colorectal Cancer 收起 <<	Phase 2	Completed	-	United Kingdom ... 展开 >> Aberdeen Royal Infirmary, Foresterhill, Aberdeen, United Kingdom, AB25 2ZN The Beatson West of Scotland Cancer Centre Glasgow, United Kingdom, G12 0YN Medical Oncology Dept. of Cancer Studies and Molecular Medicine, Leicester Royal Infirmary Leicester, United Kingdom, LEI 5WW Macmillan Lead Clinician in Gastro-intestinal Cancer Mount Vernon Cancer Centre Northwood, United Kingdom, HA6 2RN 收起 <<
NCT00831636	Ovarian Cancer	Phase 1 Phase 2	Completed	-	Belgium ... 展开 >> U.Z. Gasthuisberg, Gynecologic Oncology, Herestraat 49 Leuven, Belgium, B-3000 Italy Medical Oncology C, National Cancer Institute, Centro di Riferimento Oncologico Aviano (PN), Italy Medical Oncology B, National Cancer Institute, Via Mariano Semmola Naples, Italy, IT-80131 Department of Oncology, Catholic University of the Sacred Heart Rome, Italy, 00168 Medical Oncology, Fatebenefratelli Hospital, Isola Tiberina Rome, Italy 收起 <<
NCT01258816	Relapsed/Refractory AML	Phase 1	Completed	-	Spain ... 展开 >> ICO - Hospital Duran i Reynals Barcelona, Catalunya, Spain, 08907 Hospital General de la Vall d' Hebron Barcelona, Spain, 08035 Hospital San Pedro Alcantara Cáceres, Spain, 10003 United Kingdom Brighton & Sussex University Hospitals NHS Trust Brighton, United Kingdom, BN2 5BE University Hospital of Wales, Cardiff Cardiff, United Kingdom, CF14 4XW St Bartholomew's Hospital London, United Kingdom, EC1A 7BE 收起 <<
NCT00405743	Hematologic Malignancies ... 展开 >> AML 收起 <<	Phase 1 Phase 2	Completed	-	United States, New York ... 展开 >> Mew York Medical College, Division of Oncology Valhalla, New York, United States, 10595 United States, North Carolina Duke University Medical Center (DUMC) Durham, North Carolina, United States, 27710 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd. San Antonio, Texas, United States, 78229 France Hematology Service, Hôpital Beaujon and Hôpital Avicenne Bobigny, Paris, France, 93009 Centre Hospitalier Universitaire, CHU de Lyon, Service d'Hematologie Clinique Lyon, France, 69437 Institut Paoli-Calmettes Marseille, France, 13273 Centre Hospitalier Universitaire CHU de Toulouse, Hopital Purpan Toulouse, France, 40031-31059 Germany University Hospital Benjamin Franklin Med.Clinic III Berlin, Germany, 12200 Department of Internal Medicine Klinikum der Johann Wolfgang Goethe-Universität Medizinische Klinik II Frankfurt am Main, Germany, 60590 Westfälische Wilhelms-Universität Münster Medizinische Klinik und Polikinik Innere Medizin A Münster, Germany, 48129 Italy Institute of Hematology & Medical Oncology L and A Serágnoli University of Bologna Bologna, Italy, 40138 Universitá degli Studi di Roma Ematologia- Policlinico Tor Vergata Rome, Italy, 00133 Norway Department of Hematology, Ullevål University Hospital, University of Oslo Oslo, Norway, 0407 United Kingdom Christie Hospital Manchester, United Kingdom, M20 4BX 收起 <<

Elacytarabine {[allProObj[0].p_purity_real_show]}

Elacytarabine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Elacytarabine 质控信息

Elacytarabine 生物活性

Elacytarabine 临床研究

Elacytarabine 参考文献

Elacytarabine 实验方案

Elacytarabine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Elacytarabine {[allProObj[0].p_purity_real_show]}

Elacytarabine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Elacytarabine 质控信息

Elacytarabine 生物活性

Elacytarabine 临床研究

Elacytarabine 参考文献

Elacytarabine 实验方案

Elacytarabine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Elacytarabine 纯度/质量文件产品仅供科研